A Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma

J Drugs Dermatol. 2022 Mar 1;21(3):321-322. doi: 10.36849/JDD.6099.


Oral tranexamic acid (TXA) is a relatively new treatment option for melasma. It is thought to reduce hyperpigmentation through inhibition of the plasminogen/plasmin pathway with resulting decreases in epidermal melanocyte tyrosinase activity, inflammatory mediators, dermal neovascularization, and mast cell numbers.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Fluocinolone Acetonide / analogs & derivatives
  • Humans
  • Hyperpigmentation*
  • Melanosis* / diagnosis
  • Melanosis* / drug therapy
  • Tranexamic Acid*
  • Treatment Outcome


  • Fluocinolone Acetonide
  • Tranexamic Acid
  • fluocinolone